Detection of Pulmonary Embolism With Low-dose CT Pulmonary Angiography

NCT ID: NCT01258140

Last Updated: 2013-01-23

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

504 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-09-30

Study Completion Date

2012-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Computed tomography pulmonary angiography (CTPA) is the imaging method of choice to rule out acute pulmonary embolism based on its high sensitivity and specificity. Unfortunately, CTPA uses iodinated contrast media and can provoke contrast induced nephropathy. On the other hand, Computed tomography uses ionising radiation and is responsible for the half of the radiation exposure coming from medical sources.

Recent studies have proven that low-dose CTPA protocols using Computed tomography tube energy of 80 kVp and reduced volume of iodinated contrast media provide an increased vessel signal and good image quality at a significantly reduced patient exposure. However, there are no data on the sensitivity of low-kVp protocols.

The aim of this prospective randomized trial is to detect any difference between a normal-dose and a low-dose CTPA protocol in the diagnostic accuracy in the detection of acute pulmonary embolism (PE).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Background

Pulmonary embolism (PE) is the third most common cause of death in the U.S., with at least 650,000 cases occurring annually. Its frequency is similar in Europe. With the new generation of multi-detector Computed tomography scanners it is possible to depict the pulmonary vascular tree with a single intravenous injection of iodinated contrast medium (CM) in one breath-hold. This non-invasive method can delineate pulmonary arteries to their third-fourth branches and its overall negative predictive value lies above 99%. Therefore, Computed tomography-angiography with multi-detector scanners (MDCTA) is nowadays the preferred modality over conventional angiography or nuclear scintigraphic ventilation-perfusion (V/Q) scanning of the lung to exclude acute Pulmonary embolism(PE).

Unfortunately, Computed tomography uses ionising radiation and is already the largest contributor of radiation dose to the population in the Western countries. Most recent reports suggest that 1.5 to 2% of all fatal cancers are induced by Computed tomography in the U.S, equalling 25,420 cases per year. Furthermore, the rate of young adults with suspected Pulmonary embolism (PE) repeatedly examined with Multidetector Computed Tomography Angiography (MDCTA) is growing. Therefore, policies to reduce patient exposure are becoming more important in order to reduce the risk of developing cancer in the patients´ later life. On the other hand, elderly patients, who often has an impaired renal function or diabetes, may develop contrast induced nephropathy after the application of iodinated contrast media in, which is one of the most common causes of renal failure. Reducing iodine load in this patient group can efficiently prevent nephropathy, saving patients from dialysis and reducing medical costs.

Computed tomography protocols using low x-ray tube potential are capable of lowering radiation exposure with simultaneous increase of signal from the contrasted vessels. Furthermore, the higher vessel signal makes a reduction of the injected iodinated contrast material possible. Thus, low-kVp pulmonary CTA is warranted for routine use not only in younger patients to reduce radiation dose but also in the elderly to reduce the risk of contrast induced nephropathy.

In 2007 we reduced the tube energy of our routine pulmonary Multidetector Computed Tomography Angiography (MDCTA) protocol from 120 to 100 kVp which significantly reduced radiation dose. Our experience in more than 200 patients and results from a simulation study show that 80 kVp CTPA protocols using reduced radiation exposure by 40% and reduced volume of the injected contrast material by 25% provide an excellent image quality and a very good delineation of PE in patients weighing up to 100 kg. However, there is no clinical evidence based from prospective trials on the impact of low-dose CTPA on the detection of PE. Therefore, a large scale prospective randomised study comparing 100 kVp and 80 kVp protocols in respect sensitivity and specificity is warranted.

Objective

Assessment of diagnostic accuracy with normal-dose and low-dose CTPA in the detection of pulmonary embolism and to show the non-inferiority of the latter.

Methods

This is a monocentric, prospective randomised clinical study involving 500 patients with suspected pulmonary embolism (PE) undergoing CT pulmonary angiography. Examinations are and will be only performed if they are clinically indicated.

All patients weighing less than 100 kg with indicated CT pulmonary angiography (CTPA)to exclude pulmonary embolism (PE) between September 2008 and December 2012 are regarded as possible study candidates. The patients, if eligible, are randomly examined using a normal-dose (100 kVp, 100 mAs, 100 mL CM @ 4 mL/s) or a low-dose (80 kVp, 150 mAs, 75 mL CM @ 3 mL/s) CTPA protocol. Patients characteristics are recorded. Studies will be analyzed for pulmonary embolism (PE) localization. Findings will be compared to results from sonography of the lower extremity veins and V/Q scan of the lungs, if these were indicated, to clinical scores (revised Geneva and Wells scores) and to PE related death/ medical evidence of pulmonary emboli(PE) in 90 days following CTPA.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Embolism, Pulmonary

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

Patients examined with normal-dose Computed tomography pulmonary angiography

Group Type ACTIVE_COMPARATOR

Computed tomography pulmonary angiography

Intervention Type RADIATION

CT pulmonary angiography using iodinated contrast agent

2

Patients examined with low-dose Computed tomography pulmonary angiography

Group Type ACTIVE_COMPARATOR

Computed tomography pulmonary angiography

Intervention Type RADIATION

CT pulmonary angiography using iodinated contrast agent

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Computed tomography pulmonary angiography

CT pulmonary angiography using iodinated contrast agent

Intervention Type RADIATION

Computed tomography pulmonary angiography

CT pulmonary angiography using iodinated contrast agent

Intervention Type RADIATION

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* CTPA (CT pulmonary angiography) indicated based on clinical suspicion for pulmonary embolism
* patient's body weight \< 100 kg
* informed consent form signed by patient

Exclusion Criteria

* contraindication to iodinated contrast media
* pregnancy (if alternative imaging methods to exclude pulmonary embolism are available)
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Stanley Thomas Johnson Foundation, Bern, Switzerland

UNKNOWN

Sponsor Role collaborator

Insel Gruppe AG, University Hospital Bern

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Institute of Diagnostic, Interventional and Pediatric Radiology, University Hospital Bern

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Zsolt Szucs-Farkas, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Institute of Diagnostic, Interventional and Pediatric Radiology, University Hospital Bern

Zsolt Szucs-Farkas, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Hospital Centre Biel, Vogelsang 84, CH-2502 Biel/Bienne

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Institute of Diagnostic, Interventional and Pediatric Radiology, University Hospital Bern

Bern, Canton of Bern, Switzerland

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Switzerland

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

120/08

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.